Mineralocorticoid Receptor Antagonists and Cardiovascular Health with Kidney Failure

被引：1
作者：
Soomro, Qandeel H. [1 ]
Charytan, David M. [1 ]
机构：
[1] NYU, Dept Med, Div Nephrol, Langone Med Ctr, 550 1St Ave, New York, NY 10016 USA
来源：
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2021年 / 16卷 / 06期
关键词：
cardiovascular disease; hemodialysis; mineralocorticoid receptor antagonists; kidney failure; heart failure; ALDOSTERONE; SPIRONOLACTONE; DYSFUNCTION;
D O I：
10.2215/CJN.04460421
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：843 / 845
页数：3
相关论文
共 11 条
  • [1] Aldosterone: effects on the kidney and cardiovascular system
    Briet, Marie
    Schiffrin, Ernesto L.
    [J]. NATURE REVIEWS NEPHROLOGY, 2010, 6 (05) : 261 - 273
  • [2] Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Kidney Failure Patients Treated with Dialysis A Systematic Review and Meta-Analysis
    Chen, Kuan-Ting
    Kang, Yi-No
    Lin, Yen-Chung
    Tsai, I-Lin
    Chang, Wei-Chiao
    Fang, Te-Chao
    Wu, Mai-Szu
    Kao, Chih-Chin
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 16 (06): : 916 - 925
  • [3] Effect of Spironolactone on Left Ventricular Mass and Aortic Stiffness in Early-Stage Chronic Kidney Disease A Randomized Controlled Trial
    Edwards, Nicola C.
    Steeds, Richard P.
    Stewart, Paul M.
    Ferro, Charles J.
    Townend, Jonathan N.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (06) : 505 - 512
  • [4] Aldosterone-receptor antagonism and end-stage renal disease
    McLaughlin, N
    Gehr, TWB
    Sica, DA
    [J]. CURRENT HYPERTENSION REPORTS, 2004, 6 (04) : 327 - 330
  • [5] Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure
    Mottram, PM
    Haluska, B
    Leano, R
    Cowley, D
    Stowasser, M
    Marwick, TH
    [J]. CIRCULATION, 2004, 110 (05) : 558 - 565
  • [6] The relationship between Aldosterone level and various LV conditions in patients with End-stage renal disease
    Nesarhosseini, Vida
    Mohsenipouya, Hossein
    Makhlough, Atieh
    Jalalian, Rozita
    [J]. CASPIAN JOURNAL OF INTERNAL MEDICINE, 2019, 10 (01) : 36 - 41
  • [7] Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury
    Oestreicher, EM
    Martinez-Vasquez, D
    Stone, JR
    Jonasson, L
    Roubsanthisuk, W
    Mukasa, K
    Adler, GK
    [J]. CIRCULATION, 2003, 108 (20) : 2517 - 2523
  • [8] Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
    Pitt, B
    Remme, W
    Zannad, F
    Neaton, J
    Martinez, F
    Roniker, B
    Bittman, R
    Hurley, S
    Kleiman, J
    Gatlin, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (14) : 1309 - 1321
  • [9] The effect of spironolactone on morbidity and mortality in patients with severe heart failure
    Pitt, B
    Zannad, F
    Remme, WJ
    Cody, R
    Castaigne, A
    Perez, A
    Palensky, J
    Wittes, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (10) : 709 - 717
  • [10] Roche Gerald., 2020, MADE CHINA J
12